Cancer Innovation最新文献

{"title":"A Study Protocol for a Comprehensive Evaluation of Two Artificial Intelligence-Based Tools in Title and Abstract Screening for the Development of Evidence-Based Cancer Guidelines","authors":"Xiaomei Yao,&nbsp;Ashirbani Saha,&nbsp;Sharan Saravanan,&nbsp;Ashley Low,&nbsp;Jonathan Sussman","doi":"10.1002/cai2.70021","DOIUrl":"https://doi.org/10.1002/cai2.70021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Conducting a systematic review (SR) is a time-intensive process and represents the first phase in developing a clinical practice guideline (CPG). Completing a CPG through the Program in Evidence-Based Care (PEBC), a globally acknowledged guideline program supported by Ontario Health (Cancer Care Ontario), typically takes about 2 years. Thus, expediting an SR can significantly reduce the overall time required to complete a CPG. Our recently published review identified two artificial intelligence (AI) tools, DistillerSR and EPPI-Reviewer that reduced time in the title and abstract screening in an SR process when developing a CPG. However, the consistency and generalizability of these tools remain unclear within or across different SRs related to cancer. This study protocol aims to evaluate and compare the performance of DistillerSR and EPPI-Reviewer against human reviewers for title and abstract screening (Stage I screening) in cancer CPG development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We will conduct a retrospective simulation study to evaluate and compare the performance of DistillerSR and EPPI-Reviewer across 10 previously published CPGs by PEBC. These CPGs include the five cancer types with the highest incidence (lung, breast, prostate, colorectal, and bladder). We will run 30 simulation trials for one CPG per AI tool. Primary outcomes are workload savings and time savings in Stage I screening. The secondary outcome is the percentage of missing articles among the final included articles. This informs the accuracy and comprehensiveness of the AI tools. Descriptive and inferential statistical analysis will be conducted to evaluate the outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This is a study protocol. The data presented in the tables are illustrative examples rather than actual study results, in accordance with the journal s standard structure. All data included in the final study will be thoroughly validated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This will be the first study to investigate and compare the performance of DistillerSR and EPPI-Reviewer in Stage I screening of SRs in CPGs across different cancer types. These findings will inform the reliable use of AI tools in future cancer-related CPGs. The results from this retrospective study will need to be confirmed by prospective studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144514973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Based Methods: The Path Forward in Achieving Equity in Lung Cancer Screening and Evaluation","authors":"Stephen J. Kuperberg,&nbsp;David C. Christiani","doi":"10.1002/cai2.70019","DOIUrl":"https://doi.org/10.1002/cai2.70019","url":null,"abstract":"<p>Although lung cancer remains a global threat to public health, evidenced based advances in screening and prevention hold promise for reducing its impact on mortality. An ongoing challenge facing the clinical and research community are the glaring disparities in access to preventive services faced by ethnically and socioeconomically marginalized groups. In this context, novel approaches are needed to improve research methods and thus bolster our ability to improve outcomes. Artificial intelligence (AI) applications such as machine learning and natural language processing hold promise as catalysts in this process, enhancing speed, accuracy and capability. This perspective will highlight the potential of AI methods as essential tool for growth across the lung cancer diagnostic continuum from screening to diagnosis.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden of Breast Cancer in Adolescents and Young Adults Aged 15–39 Years From 1990 to 2021 Based on the Global Burden of Disease Study 2021","authors":"Zheng Qu,&nbsp;Zheng Li,&nbsp;Shengbin Pei,&nbsp;Ye Lu,&nbsp;Qiang Liu,&nbsp;Peikai Ding,&nbsp;Yazhe Yang,&nbsp;Luxiao Zhang,&nbsp;Jing Wang,&nbsp;Yi Fang","doi":"10.1002/cai2.70016","DOIUrl":"https://doi.org/10.1002/cai2.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer (BC) remains a significant global public health challenge, and its incidence and mortality rates among adolescents and young adults (AYAs) aged 15–39 years are increasing. Compared with older adults, AYAs often face poorer prognoses and a higher disease burden. Understanding the trends and determinants of BC burden in AYAs is crucial for guiding preventive measures, early detection programs, and treatment strategies. The aim of this study is to systematically investigate the trends and distribution of the BC burden among AYAs aged 15–39 years across regions and countries and identify the contributing risk factors and disparities in incidence, mortality, and disability-adjusted life years (DALYs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data on BC were collected from the Global Burden of Disease (GBD) 2021 database. The number of cases, age-standardized rates, mortality, and DALYs for BC were assessed for 204 countries and territories from 1990 to 2021. Joinpoint regression analysis was used to calculate the average annual percentage changes (AAPCs) in incidence, mortality, and DALYs. Risk factors that contribute to the BC burden were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>According to GBD 2021 estimates, 180,791 new BC cases and 42,055 related deaths were observed among AYAs globally. Between 1990 and 2021, the global incidence rate increased by 33.4%, with the highest incidence observed in regions with a high sociodemographic index (SDI) and the highest mortality rates in low-SDI regions. Incidence rates in women showed a significant upward trend (AAPC, 3.03) and peaked in North Africa and the Middle East, whereas the most rapid increase in incidence in men was noted in East Asia (AAPC, 4.87). Projections indicated a decline in age-standardized incidence rates across most European countries by 2050, in contrast to rising trends in Asia and Africa. Risk factor analysis identified dietary risks (10.5%), tobacco smoking (2%), and high fasting plasma glucose (1.6%) as major contributors to DALYs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The global burden of AYA BC has increased significantly, particularly in regions with a middle and low SDI. The findings highlight the need for targeted preventive interventions for high-risk populations and provide critical insights for developing regional control strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers","authors":"Haixia Cheng,&nbsp;Guangwen Yuan,&nbsp;Leilei Liang,&nbsp;Tiantian Wang,&nbsp;Jiarun Zhu,&nbsp;Hongying Yang,&nbsp;Zhendiao Zhou,&nbsp;Pei Wang,&nbsp;Qianqian Song,&nbsp;Yuchen Jiao,&nbsp;Mei Liu,&nbsp;Lingying Wu","doi":"10.1002/cai2.70014","DOIUrl":"https://doi.org/10.1002/cai2.70014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To assess whether changes in TP53 mutations and copy number alterations (CNA) in plasma circulating tumor DNA (ctDNA) can predict treatment response and prognosis in platinum-resistant recurrent ovarian cancer (PROC) patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-seven PROC patients were recruited. Forty-three patients with matched tumor and plasma samples were analyzed via both a tumor-informed ctDNA assay (TICA) and a tumor-uninformed ctDNA assay (TUCA) profiling TP53 mutations and CNA. The TUCA algorithm was optimized based on TICA results. Fourteen patients without matched tumor tissues were used just for TUCA analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A ctDNA decrease of ≥ 80% from baseline or ctDNA negativity during treatment detected by the TICA (defined as favorable TICA changes) strategy before the third cycle predicted the best overall response, with 81.8% sensitivity and 84.6% specificity. The TUCA strategy was defined as a combination of TP53 mutations and CNA changes. A favorable TUCA change before the third cycle predicted the best overall response, with 90.0% sensitivity and 63.2% specificity. In 12 patients without clinical benefit, the median lead time to detect drug resistance from TUCA to the Response Evaluation Criteria in Solid Tumors was 86.0 days. Patients with favorable ctDNA changes (<i>n</i> = 15) detected by TUCA before the third cycle had a median progression-free survival of 9.2 months, versus 3.6 months in those without (<i>n</i> = 34) (HR: 2.88; 95% CI 1.56–5.30; log-rank <i>p</i> = 0.0008).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Similar to TICA, ctDNA changes detected by TUCA combined with TP53 mutations and CNA could predict treatment response and prognosis in PROC patients without requiring tumor tissues.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis","authors":"Zuowei Zou,&nbsp;Luhua Xia,&nbsp;Saikang Tang,&nbsp;Lin Lin,&nbsp;Quanyang Wu,&nbsp;Donghui Hou,&nbsp;Shijun Zhao","doi":"10.1002/cai2.70015","DOIUrl":"https://doi.org/10.1002/cai2.70015","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ovarian cancer patients with elevated serum CA125 levels after operation have a high incidence of relapse or metastasis. ¹⁸F-FDG PET/CT is an effective imaging method for identifying recurrent or metastatic lesions. This study systematically investigated the diagnostic value of ¹⁸F-FDG PET/CT in this patient population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of PubMed, Embase, Cochrane Library (Central), Web of Science (SCI-Expanded), and Chinese databases (CNKI, VIP database, Wan Fang Data, CBM) was performed. Studies that evaluated the diagnostic value of ¹⁸F-FDG PET/CT for relapse or dissemination in postoperative ovarian cancer patients with elevated serum CA125 levels were included. The methodological quality of the studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Data were analyzed for heterogeneity using Meta-Disc 1.4 software. Sensitivity analysis and release bias evaluation were conducted using STATA 14.0 software.</p>\u0000 \u0000 <p>Thirteen studies (including 421 female patients) qualified for the meta-analysis. The pooled sensitivity and specificity of ¹⁸F-FDG PET/CT were 0.94 (95% CI: 0.91–0.97) and 0.83 (95% CI: 0.71–0.91), respectively. The pooled positive likelihood proportion was 4.59 (95% CI: 2.81–7.51), the pooled negative likelihood proportion was 0.09 (95% CI: 0.05–0.15), and the pooled diagnostic odds ratio was 64.22 (95% CI: 27.21–151.57). The area under the curve was 0.9379. A sensitivity analysis and publication bias test indicated that the outcomes were steady, and there was no reporting bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>¹⁸F-FDG PET/CT has high diagnostic veracity for identifying recurrence or metastasis in ovarian cancer cases with increased serum CA125 levels after surgery. It can accurately detect recurrent or metastatic lesions, providing valuable information for clinical decision-making.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Identification of Novel Prognostic and Predictive Biomarkers in Breast Cancer via the Elucidation of Tumor Ecotypes Using Ecotyper","authors":"Feng Du,&nbsp;Jie Ju,&nbsp;Fangchao Zheng,&nbsp;Songlin Gao,&nbsp;Peng Yuan","doi":"10.1002/cai2.70013","DOIUrl":"https://doi.org/10.1002/cai2.70013","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is a highly heterogeneous disease, characterized by tumor and nontumor cells at various cell states. Ecotyper is an innovative machine learning framework that quantifies the tumor microenvironment and delineates the tumor ecosystem, demonstrating clinical significance. However, further validation is needed in breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ecotyper was applied to identify multiple cellular states and tumor ecotypes using large-scale breast cancer bulk sequencing data, followed by a detailed analysis of their associations with clinical classification, molecular subtypes, survival prognosis, and immunotherapy response. Identified subtypes were further characterized using single-cell and spatial data sets to reveal molecular profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In a comprehensive analysis of 6578 breast cancer samples from four data sets, Ecotyper identified 69 cellular states and 10 tumor ecotypes. Of these, 37 cellular states significantly correlated with overall survival. Notably, specific states within epithelial cells, macrophages/monocytes, and fibroblasts were linked to a worse prognosis. CE2 abundance was identified as the most significant marker indicating unfavorable prognosis and was further validated in an additional data set of 116 HER2-negative patients. These biomarkers also indicated the efficacy of neoadjuvant immunotherapy in breast cancer. CE2-high cancers were characterized by an abundance of basal-like epithelial cells, scant lymphocytic infiltration, and activation of hypoxia signaling. Single-cell analysis showed that CE2-high areas were rich in SPP1-positive tumor-associated macrophages(TAM), basal-like epithelial cells, and hypoxic cancer-associated fibroblasts(CAF). Spatially, these regions were often peripheral in triple-negative breast cancer, adjacent to fibrotic/necrotic zones. Multiplex immunofluorescence confirmed the enrichment of SPP1+CD68+TAM and HIF1A+SMA+CAF in hypoxic triple-negative breast cancer (TNBC) regions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ecotyper identified novel biomarkers for breast cancer prognosis and treatment prediction. The CE2-high region may represent a hypoxic immune-suppressive niche.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144140424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Evaluation of the Urinary Microbiota Associated With Bladder Cancer","authors":"Nannan Li,&nbsp;Lei Wang,&nbsp;Qin Yang,&nbsp;Fuqiang Li,&nbsp;Zhun Shi,&nbsp;Xiujie Feng,&nbsp;Liwei Zhang,&nbsp;Xiaojian Li,&nbsp;Xin Jin,&nbsp;Shida Zhu,&nbsp;Kui Wu,&nbsp;Ningchen Li","doi":"10.1002/cai2.70012","DOIUrl":"https://doi.org/10.1002/cai2.70012","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bladder cancer is a common malignancy of the genitourinary system. Recent studies have confirmed the existence of microorganisms in urine. This study aimed to characterize changes in the urinary microbiota of Chinese bladder cancer patients and determine differences between patients with muscle-invasive bladder cancer (MIBC) and those with non-muscle-invasive bladder cancer (NMIBC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Urine samples were collected from 64 patients with bladder cancer and 94 disease-free controls using the clean catch method and sequenced by 16S rRNA gene sequencing. Sequencing reads were filtered by VSEARCH and clustered by UPARSE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significant associations were found between urinary microbiota and factors such as sex, age, and disease status. After age adjustment, differences in beta diversity were observed between healthy men and women, cancer patients and healthy controls, and NMIBC and MIBC patients. The cancer patients had an increased abundance of 14 bacterial genera, including <i>Stenotrophomonas</i>, <i>Propionibacterium</i>, and <i>Acinetobacter</i>. Notably, <i>Peptoniphilus</i> spp. were enriched in high-risk MIBC patients, indicating their potential as a risk marker. Functional prediction via PICRUSt analysis suggested enriched metabolic pathways in specific disease groups. Furthermore, molecular ecological network analysis revealed differences based on sex and disease type.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This significant microbial diversity indicates a potential correlation between urinary microbiota dysbiosis and bladder cancer, with implications for risk stratification and disease management. The identified urinary microbiota may serve as noninvasive markers for bladder cancer, warranting further validation in larger cohorts. This study provides a foundation for further research on the mechanisms of bladder cancer progression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Depth Analysis of the Necessity and Optimization Strategies for Adjuvant Radiotherapy Following Neoadjuvant Immunotherapy in the New Era of Esophageal Cancer Treatment","authors":"Guohui Liu,&nbsp;Yao Su,&nbsp;Yunlong He,&nbsp;Hanqing Hu","doi":"10.1002/cai2.70010","DOIUrl":"https://doi.org/10.1002/cai2.70010","url":null,"abstract":"<p>As immunotherapy rises to prominence in cancer treatment, the therapeutic approach to esophageal cancer is undergoing significant transformations. This review emphasizes the necessity and optimization pathways for adjuvant postoperative radiotherapy after neoadjuvant therapy in patients with esophageal cancer in the immunotherapy era. Initially, we review the advancements in neoadjuvant treatment strategies. Subsequently, we evaluate the role of postoperative radiotherapy and the latest advancements in radiotherapy target volume definition and dose optimization following neoadjuvant therapy, as well as the implications of tumor immunotherapy on postoperative radiotherapy strategies. In conclusion, in the new era of immunotherapy, postoperative radiotherapy following neoadjuvant therapy for esophageal cancer holds significant value. Optimization strategies should follow individualized treatment principles and comprehensively consider tumor biology, patient status, and treatment resources to achieve optimal therapeutic outcomes and quality of life, thereby driving continuous innovation in esophageal cancer treatment.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SKIL Promotes Pancreatic Cancer Metastasis by Inhibiting TSPYL2 to Activate the TGF-β Pathway","authors":"Chenxi Wang,&nbsp;Weiwei Song,&nbsp;Yixuan Zhang,&nbsp;Hongming Deng,&nbsp;Zixiang Zhou,&nbsp;Jing Zhu,&nbsp;Xiaobing Wang","doi":"10.1002/cai2.70011","DOIUrl":"https://doi.org/10.1002/cai2.70011","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pancreatic adenocarcinoma (PAAD) represents a highly fatal form of cancer. The 5-year survival rate for patients with this disease is only around 10%. A significant hurdle in its management is the absence of characteristic early-stage symptoms. As a result, a large majority of pancreatic cancer patients are diagnosed when the disease has reached an advanced stage or has metastasized. Consequently, taking measures to suppress the occurrence of metastasis in pancreatic cancer can bring about a substantial improvement in patients' survival rates and overall prognosis. <i>SKIL</i>, known to promote cancer progression, is implicated in cell proliferation, epithelial–mesenchymal transition (EMT), and metastasis, but its specific function in pancreatic cancer remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We investigated the effects of <i>SKIL</i> on the proliferation, apoptosis, and metastasis of pancreatic cancer cells. Through ChIP-seq, we identified the <i>SKIL</i> downstream target gene and further explored the mechanism by which <i>SKIL</i> regulates the metastasis of pancreatic cancer cells through functional experiments and Western blot.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A high level of <i>SKIL</i> expression is associated with an unfavorable prognosis in PAAD; it promotes cell migration and EMT. Through ChIP-seq analysis, we identified that <i>SKIL</i> inhibits <i>TSPYL2</i>, a nuclear protein regulating the TGF-β pathway by binding to the <i>TGFB1</i> promoter. Further studies carried out by us confirmed that <i>SKIL</i> modulates the TGF-β pathway via <i>TSPYL2</i>, facilitating EMT and metastasis in pancreatic cancer cells, independent of Smad4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings reveal a novel regulatory mechanism involving <i>SKIL</i>, <i>TSPYL2</i>, and the TGF-β pathway, offering new therapeutic targets for PAAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)","authors":"The Breast Cancer Expert Committee of the National Quality Control Center for Cancer,&nbsp;The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center,&nbsp;The Society of Clinical Research on Oncology Medications of the China Anti-Cancer Association,&nbsp;The Society of Onco-Pathology of the China Anti-Cancer Association","doi":"10.1002/cai2.70008","DOIUrl":"https://doi.org/10.1002/cai2.70008","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer. Randomized clinical trials have shown that PI3K/AKT/mTOR inhibitors deliver significant clinical benefits, particularly for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 2022, the Breast Cancer Expert Committee of the National Cancer Quality Control Center convened specialists in related fields to draft the “Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Advanced Breast Cancer.” This consensus raised awareness of these inhibitors among oncologists in China and improved the precision of clinical decision-making. In recent years, growing evidence has emphasized the importance of targeting the PAM pathway, reflected in the approval of several innovative agents. This consensus is an updated 2025 edition that retains the foundational structure of the 2022 edition while incorporating notable updates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Updates to the consensus include the introduction of newly approved PAM pathway inhibitors, updated data from recent clinical trials, and expanded therapeutic applications. The revised guidance also offers updated recommendations for genetic testing to detect alterations in relevant pathways. The section on managing drug-related adverse events has been significantly expanded, providing detailed insights into different types of adverse events and their management. These updates aim to enhance the clinical application of PAM pathway inhibitors, promote precision medicine, and ultimately, improve survival outcomes for patients with breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}